Benign recurrent intrahepatic cholestasis type 1
MONDO:0009469Benign recurrent intrahepatic cholestasis 1 (BRIC1) is characterized by episodes of liver dysfunction called cholestasis, during which the liver cells have a reduced ability to release a digestive fluid called bile. These episodes can last from weeks to months, and the time between them, during which there are usually no symptoms, can vary from weeks to years.Most people with BRIC1have their first episode of cholestasisintheir teens or twenties. Symptoms oftenpresent with severe itchiness, followed by yellowing of the skin and whites of the eyes (jaundice) a few weeks later. BRIC1 is caused by mutations in the ATP8B1 gene. This condition is inherited in an autosomal recessive pattern.BRIC1generally does not cause lasting damage to the liver. However, in rare cases, episodes of liver dysfunction may develop into a more severe, permanent form of liver disease known as progressive familial intrahepatic cholestasis (PFIC). BRIC and PFIC are sometimes considered to be part of a spectrum of intrahepatic cholestasis disorders of varying severity.
Also known as: cholestasis, benign recurrent intrahepatic, ATP8B1 benign recurrent intrahepatic cholestasis, BRIC1, Bric type 1, benign recurrent intrahepatic cholestasis caused by mutation in ATP8B1, cholestasis, benign recurrent intrahepatic, type 1, Summerskill syndrome, benign recurrent intrahepatic cholestasis 1
9 clinical trials for this condition and its sub-types, 0 tagged with Benign recurrent intrahepatic cholestasis type 1 itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Promising long-term results for rare liver disease drug in kids
Disease control CompletedThis study looked at the long-term safety and effectiveness of a drug called A4250 (odevixibat) in 116 children with progressive familial intrahepatic cholestasis (PFIC), a rare liver disease. The children took the drug for up to 72 weeks. The study measured changes in bile acid …
Phase 3 • Sponsor: Albireo, an Ipsen Company • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New imaging tool aims to sharpen bile duct diagnosis
Diagnosis CompletedThis completed study tested a device called NvisionVLE® that helps doctors see bile duct details during a procedure called ERCP. Only 3 adults who had the procedure between 2017 and 2019 took part. The goal was to check if the device is safe and can better find abnormalities to g…
Sponsor: Methodist Health System • Aim: Diagnosis
Last updated Jun 27, 2026 12:00 UTC